Retrospective Clinical Validation of HepatoPredict

Launched by OPHIOMICS · Mar 18, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new tool called HepatoPredict, which helps doctors make better decisions for patients with Hepatocellular Carcinoma (HCC), the most common type of liver cancer. HepatoPredict analyzes a small sample of the tumor and combines this information with imaging tests, like scans, to predict whether a patient is likely to stay cancer-free after liver surgery or transplantation. This tool aims to improve how doctors select patients for treatment, ensuring that those who will benefit most from surgery receive it, while also identifying those who might not benefit.

To participate in this study, individuals need to be at least 18 years old and have been diagnosed with HCC, having undergone either liver transplantation or surgical removal of the tumor, with at least five years of follow-up. Participants will have their outcomes assessed to see how well HepatoPredict can predict their chances of remaining cancer-free and surviving overall after their treatment. The trial is not yet recruiting participants, but it aims to provide valuable insights that could enhance treatment options for patients with liver cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years old.
• • Patients with HCC that underwent transplantation, with at least 5 years follow-up.
• • Patients with HCC that underwent surgical resection, with at least 5 years follow-up.
• • Completed informed consent process (for patient candidates that are still alive).
• Exclusion Criteria:
• • Age \< 18 years old.
• • Other non-HCC liver cancers patients.
• • Patients with tumor extra-hepatic spread at diagnosis.